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Introduction: The role of Interleukin 28B (IL-28B) genetic polymorphisms in inﬂuencing the occurrence
of biliary complications after liver transplantation has never been evaluated. This study aimed to
investigate whether IL-28B rs12979860C/T polymorphisms associate with the occurrence of biliary
complications after liver transplantation and if these complications may inﬂuence survival. Methods:
One hundred seventy one recipients (133 males) who underwent liver transplantation were recruited. To
conﬁrm the mechanical etiology of cholestasis, endoscopic cholangio pancreatography, percutaneous
and/or trans-Kehr cholangiography or cholangio magnetic resonance were performed. Two main clinical
pictures were identiﬁed: biliary strictures and biliary leakage. Immunosuppressive therapy was based on
cyclosporine (N ¼ 54) or tacrolimus (N ¼ 117), in association with steroids during the ﬁrst month after
operation. IL-28B rs12979860C/T genotypes were detected by means of polymerase chain reaction. Re-
sults: Forty patients (23.4%) presented anastomotic strictures, 7 (4.1%) non-anastomotic strictures, 10
(5.8%) leakage, 8 (4.7%) leakage plus anastomotic strictures. IL-28B rs12979860C/C genotype in associ-
ation with cyclosporin was found to be an independent predictor of anastomotic strictures occurrence
(p ¼ 0.008). A signiﬁcant difference in 5 years survival was observed between patients with viral etiology
of liver disease experiencing either anastomotic or non-anastomotic strictures (16/23) and the remaining
patients (104/112, p ¼ 0.001). Conclusions: In recipients carrying rs12979860 IL-28B C/C genotype the
use of cyclosporine seems to contribute to enhance the probability of developing biliary complications
which in hepatitis B and C positives appear to reduce patient survival. If conﬁrmed in larger studies the
use of cyclosporine in these patients could be revised.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Biliary complications are probably the most frequent problem
that transplant hepatologists and surgeons have to manage
following liver transplantation (LT) [1e3]. They are generallyiutto).
by Elsevier Ltd. All rights reservedclassiﬁed according to their anatomical location into anastomotic
and non-anastomotic complications, because of the different clin-
ical presentation and management. Anastomotic complications
comprise leakage and stricture. The overall reported incidence of
anastomotic strictures (AS), that are by far the most frequent biliary
complications, ranges between 13% and 19% after full size and living
donor liver transplantation (LDLT) respectively [2,4]. Their inci-
dence is increasing in the post MELD era, reaching 16.7% in some
series, probably because of the use of marginal grafts from older.
Patients transplanted between 
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HCV/HIV co-infected recipients
N = 1
Living donor liver transplanted
N = 3
Died during the 1
st
month after transplant
N = 16
Lost of follow-up
Selected for the study
N = 171
N = 191
N = 190
N = 187
Fig. 1. Flow chart showing the selection of patients recruited in the study.
Table 1
Main demographic and clinical characteristics of studied population (N ¼ 171).
Continuous variables are presented as median (range) and categorical variables as
frequencies (%).
Recipient age, years 56 (25e68)
Donor age, years 51 (11e81)
Recipient male gender 133 (77.8%)
Donor male gender 115 (67.3%)
Split liver 13 (7.6%)
MELD 14 (6e40)
D-MELD 670 (99e2479)
Recipient BMI at LT, kg/m2 25 (15e35)
CMV reactivation 35 (20.5%)
Kehr T tube 23 (13.5%)
Viral etiology (HCV or HBV related) 85 (49.7%)
Presence of hepatocellular carcinoma before LT 61 (35.7%)
Total ischemia time, min 460 (128e955)
Use of University of Wisconsin solution 45 (26.3%)
Use of cyclosporine 54 (31.6%)
Presence of diabetes mellitus before LT 44 (25.7%)
Presence of systemic arterial hypertension before LT 50 (29.2%)
Patients with at least 1 moderate to severe ACR 36 (21.1%)
Hepatic artery resistance index 1 month after LT 0.67 (0.33e0.87)
Hepatic artery thrombosis 5 (2.9%)
Steroid treatment duration, days 137 (0e868)
MELD ¼ Model of End Stage Liver Disease; BMI ¼ body mass index;
CMV¼ Cytomegalovirus; HCV¼ hepatitis C virus; HBV¼ hepatitis B virus; LT¼ liver
transplantation; ACR ¼ acute cellular rejection.
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rence of non-anastomotic strictures (NAS), in relationship to a
suboptimal biliary blood supply or to an enhanced susceptibility of
the biliary tree to ischemic damage [2,6]. The treatment of AS
generally consists of endoscopic balloon dilatation with or without
stents placement. This approach can solve up to 60e90% of AS and
generally requires repeated sessions and progressive dilatation up
to the complete resolution of the stricture [7].
Among the risk factors described for the occurrence of AS, most
of them related to surgical and technical aspects [5,8], recent
studies suggested an inﬂuence exerted by the cross-talk between
donor and recipient immune responses and by the degree of
inﬂammation. In fact, Jacob et al. [9] found that AS occurrence was
associated with recipient fractalkine receptor (CX3CR1)-V249I
polymorphism andwith the presence of donor-speciﬁc anti-human
leucocyte antigen (HLA) class II antibodies. In the same study, pa-
tients with AS exhibited higher serum levels of IFN-g, IL-6 and IL-
10. Therefore, a new scenario, where the innate immune response
can play an important role in the occurrence of biliary complica-
tions, may be hypothesized.
Interleukin 28B (IL-28B) gene encodes for Interferon lambda 3
which is a cytokine involved in the innate immune response [10,11].
Both donor and recipient IL-28B rs12979860 genetic poly-
morphisms have been implicated in the severity of HCV recurrence
and in response to antiviral treatment after LT [12]. The simulta-
neous carriage in donor and recipients of IL-28B CC genotype has
been associated with a better response to antiviral therapy for HCV
recurrence [13,14] but conﬂicting results have been published
considering the effect of IL-28B genetic polymorphisms on graft
survival both in HCV positive and HCV negative recipients [12,15].
Moreover, an association has been demonstrated between IL-28B
polymorphisms and the occurrence of post LT diabetes mellitus
and acute cellular rejection [16,17]. These data seem to support the
evidence that this cytokine could play an important role in the
modulation of immune response in liver transplanted patients. No
data have been reported regarding the potential inﬂuence of IL-28B
genetic polymorphisms on the occurrence of biliary complications
after LT.
The aim of this retrospective study was to investigate whether
IL-28B rs12979860C/T polymorphisms may be associated with the
development of biliary complications after liver transplantation in
HCV negative and positive recipients.
2. Patients and methods
Two hundred twenty ﬁve consecutive adult recipients who
underwent liver transplant at the University of Udine from January,
1st 2004 to November, 30th 2010 were considered for the study.
Thirty four patients were excluded because of HIV co-infection, 1
for having received an LDLT, 3 because died within 30 days after
transplant and 16 since they were lost of follow-up (Fig. 1). The
remaining 171 patients were enrolled in the study. The protocol for
the research project has been approved by our Ethical Committee.
The study conforms to the provision of the declaration of Helsinki;
all patients gave an informed consent. All clinical and demographic
data were recorded from the Transplant Center database and are
reported in Table 1. Biliary-digestive anastomosis during LT was at
discretion of the surgeon and generally reserved to patients
transplanted for cholestatic liver diseases such as primary scle-
rosing cholangitis. In the remaining patients chol-
edochoecholedocho terminal anastomosis was performed with or
without the placement of Kehr T tube. In the former patients a
trans-Kehr cholangiography was done within 10 days after LT or
when clinically required. Kehr T tube was removed 3 months after
transplant adopting the endoscopic retrogradecholangiopancreatography (ERCP) rendez-vous technique which
was always associated with the placement of a biliary stent to
prevent biliary leakage.
The suspicion of mechanical cholestatic syndrome derived from
the increase in serum levels of alkaline phosphatase, bilirubin and
gamma glutamyl transpeptidase, in conjunction with ultrasound
evident dilatation of intra-hepatic biliary three with the patency of
hepatic artery and portal vein. To conﬁrm the mechanical etiology
of cholestasis, ERCP, percutaneous and/or trans-Kehr cholangiog-
raphy and magnetic resonance imaging (MRI) of biliary three were
performed. Two main clinical pictures were identiﬁed: presence of
biliary strictures (AS and NAS) and biliary leakage. Biliary strictures
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three needing a therapeutic intervention such as endoscopic
ballooning and/or insertion or substitution of a previously placed
biliary stent. Biliary leakage was deﬁned by the presence of biloma.
Immunosuppressive therapy was based on cyclosporine (CSA,
N ¼ 54) or tacrolimus (TAC, N ¼ 117), in association with steroids
during the ﬁrst month after LT. Dosage of CSA was based on pre-
dose plasma concentrations, with targeted values from 250 to
350 mg/L within the ﬁrst 6 weeks after transplant and from 50 to
150 mg/L thereafter. Dosage of TAC was based on pre-dose plasma
concentrations, with targeted values from 10 to 15 mg/L during the
ﬁrst 6 weeks after transplantation and from 5 to 10 mg/L thereafter.
In all patients both CSA and TAC serum concentrations were
measured at the ﬁrst day, after the starting loading dose, and
thereafter at the following days: 15, 30, 60, 90, 120, 150, 180 and
360. The daily concentration of the immunosuppressive drugs was
estimated calculating the area under the curve (AUC) adopting the
trapezoid rule. Corticosteroid therapy was started during liver
transplant with the administration of 500 mg of metilprednisolone
i.v., followed by metilprednisolone 250 mg i.v. in the second and in
the third day after the operation. Oral prednisone at a dosage of
40 mg daily was started at the fourth day after transplant. Corti-
costeroids were tapered and suspended within 4 months. Twenty
four patients were treated with a steroid free immunosuppressive
regimen.Table 2
Associations between demographic and clinical variables and occurrence of biliary
anastomotic stricture following liver transplantation. The statistical analysis was
performed by means of Pearson chi square test.
Biliary anastomotic stricture
Yes N ¼ 40
(23.4%)
No N ¼ 131
(76.6%)
p
Recipient age >55 years 24 (60.0%) 75 (57.3%) 0.758
Donor age >45 years 27 (67.5%) 75 (57.3%) 0.247
Recipient male gender 32 (80.0%) 101 (77.1%) 0.6992.1. Molecular biology
Identiﬁcation of IL-28B genotype polymorphism rs12979860C/T
was done as previously described [18]. In brief, a polymerase chain
reaction-based restriction fragment length polymorphism assay
technique was used. DNA was extracted fromwhole blood samples
using QIAamp DNA Blood Mini Kit (Qiagen Milan, Italy). In a total
volume of 10 mL an amplicon of 242-base pairs, using the 50-
GCTTATCGCATACGGCTAGG-30 and 50-AGGCTCAGGGTCAATCACAG-
30 primers, was obtained. The thermal proﬁle adopted was 90 for
3000, 62 C for 3000, 72 C for 3000 repeated for 40 cycles in a Techne
TC-5000 thermal cycler. The amplicons obtained were then diges-
ted overnight at 60 Cwith one unit of BstU-I (New England Biolabs,
Hitchin, UK) restriction enzyme. The fragments obtained were of
135 þ 82 þ 25 bp for the C allele and of 160 þ 82 bp for the T allele
variant respectively, stained with ethidium bromide and resolved
in a 3.5% agarose gel electrophoresis.Donor male gender 31 (77.5%) 84 (64.1%) 0.115
MELD >14 17 (42.5%) 58 (44.3%) 0.843
D-MELD >750 15 (37.5%) 52 (39.7%) 0.803
Recipient BMI at LT > 25 kg/m2 20 (50.0%) 52 (39.7%) 0.248
CMV reactivation 8 (20.0%) 27 (20.6%) 0.933
Kehr T tube 12 (30.0%) 11 (8.4%) <0.001
HCV and/or HBV etiology 16 (40.0%) 69 (52.7%) 0.161
Total ischemia time >460 min 14 (35.0%) 54 (41.2%) 0.482
Use of University of Wisconsin
solution
7 (17.5%) 38 (29.0%) 0.148
Use of cyclosporine 18 (45.0%) 36 (27.5%) 0.037
Presence of DM before LT 12 (30.0%) 32 (24.4%) 0.480
Steroid treatment duration >120
days
29 (72.5%) 82 (62.6%) 0.251
Occurrence of hepatic artery
thrombosis
1 (2.5%) 4 (3.1%) 0.856
Hepatic artery RI > 0.67 1 month
after LT
21 (52.5%) 58 (44.3%) 0.361
Occurrence of moderate to severe
ACR
11 (27.5%) 25 (19.1%) 0.253
MELD ¼ Model of End Stage Liver Disease; BMI ¼ body mass index;
CMV¼ Cytomegalovirus; HCV¼ hepatitis C virus; HBV¼ hepatitis B virus; LT¼ liver
transplantation; ACR ¼ acute cellular rejection.2.2. Statistical analysis
Statistical analysis of data was performed using the BMDP dy-
namic statistical software package 7.0 (Statistical Solutions, Cork,
Ireland). Categorical variables have been presented as frequencies
and continuous variables as medians (range). Pearson chi-squared
test and Chi-square test for linear trend, when appropriate, have
been applied to detect associations between categorical variables.
The chi-square G test “Goodness of Fit” was employed to verify
whether the proportions of the polymorphism were distributed in
accordance with the HardyeWeinberg equation. Step-wise logistic
regression analysis has been used to explore independent pre-
dictors of AS. Kaplan Mayer and Mantel Cox test were employed to
evaluate predictors of survival. Cox proportional hazard model was
used to identify independent predictors in survival analysis. Sta-
tistical signiﬁcance has been considered for p values <0.05.3. Results
3.1. Occurrence of biliary complications
Forty patients (23.4%) presented AS, 7 patients (4.1%) presented
NAS, 10 patients (5.8%) leakage and 8 (4.7%) leakage plus AS. By
means of One-Way ANOVA for linear trend, mean time for the
occurrence of biliary complications signiﬁcantly increased from
biliary leakage (2.1 months) to NAS (8.4 months) to AS (10.9
months, p ¼ 0.015 for linear trend).3.2. Risk factors associated with the occurrence of AS
Table 2 illustrates the association between demographic and
clinical variables and the occurrence of AS. At the univariate anal-
ysis, the only clinical feature strongly associated with AS was the
use of Kehr T tube. Moreover, use of CSA as the main immune-
suppressive agent was slightly associated with a higher probabil-
ity to develop AS.3.3. IL-28B rs12979860C/T polymorphism and the occurrence of AS
Recipient IL-28B genotypic frequencies were: C/C ¼ 71 (41.5%),
C/T ¼ 83 (48.5%), T/T ¼ 17 (10.0%). The allelic frequencies were:
C ¼ 0.658 and T ¼ 0.342. The genotypic frequencies observed did
not differ from what expected according to the HardyeWeinberg
formula (p ¼ 0.306). A signiﬁcant association was observed be-
tween recipient IL-28B rs12979860C/T polymorphism and occur-
rence of AS which was found in 22/71 (31.0%) patients carrying the
C/C genotype, in 16/83 (19.3%) carrying the C/Tgenotype and in 2/17
(11.8%) carrying the T/T genotype (p ¼ 0.039 for linear trend).
Table 3
Summary of the results of stepwise logistic regression analysis in the prediction of
biliary anastomotic strictures occurrence. Covariates were those reported in Table 2,
IL-28B polymorphism (C/C Vs T/*) and the interaction between IL-28B poly-
morphism and type of immunosuppression (C/C plus cyclosporine use Vs the
remaining patients).
Coefﬁcient S.E. O.R. 95% C.I. P
Kehr T tube adoption 1.697 0.499 5.46 2.04e14.6 0.001
C/C genotype and cyclosporine use 1.435 0.516 4.20 1.52e11.6 0.008
Donor male gender 0.959 0.471 2.61 1.03e6.61 0.032
S.E. ¼ standard error; O.R. ¼ odds ratio; C.I. ¼ conﬁdence interval.
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relationship with the immune suppressive regimen
Fig. 2 shows the relationship between IL-28B rs12979860C/T
polymorphisms (C/C vs T/* genotypes) and the occurrence of AS.
Data were presented considering all patients and dividing them on
the basis of the type of immunosuppressive regimen adopted (CSA
or TAC). The carriage of IL-28B C/C genotype was signiﬁcantly
associated with a more frequent development of AS (22/71 vs 18/
100, p ¼ 0.048); this was conﬁrmed in patients treated with CSA
(10/20 vs 8/34, p ¼ 0.046) but not in patients treated with TAC (12/
51 vs 10/66, p ¼ 0.250). By logistic regression analysis the inter-
action between IL-28B polymorphism and CSA was found to be an
independent predictor of AS occurrence, together with receiving a
graft from a male donor and the use of a Kehr-T tube (Table 3).3.5. Management of biliary complications
Biliary complications were managed as follows: 53 (81.5%) had
subjected to ERCP and 12 (18.5%) to percutaneous-cholangio-
pancreatography (PCCP); 9 (13.8%) of the latter underwent to
both procedures. In patients who were subjected to ERCP, 13 per-
formed the procedure once, 12 twice, 11 thrice, 5 fourfold, 9 ﬁve-
fold, 4 sixfold, 4 sevenfold, 1 eightfold, 2 ninefold and 1 tenfold. In
the 62 patients who underwent to ERCP a signiﬁcant association
was observed between carriage of C/C genotype plus CSA use and
the need to be subjected to more than 3 procedures (7/10 vs 19/52,
p ¼ 0.049).3.6. Biliary complications and survival
Five years survival among recipients who completed at least one
year of follow-up after LT (N ¼ 135) was found to be signiﬁcantly
worse in patients who experienced the occurrence of a biliary
stricture, either AS or NAS (ManteleCox p ¼ 0.046). In particular
this was conﬁrmed in patients with viral etiology of liver disease
(HCVþHBV, N¼ 64, Fig. 3 panel A) while it was not observed in theAll patients
S
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Fig. 2. Relationship between IL-28B rs12979860C/T polymorphisms (C/C vs T/* geno-
types) and the occurrence of anastomotic strictures. Data were presented considering
all patients and dividing them on the basis of the type of immunosuppressive regimen
adopted (Cyclosporin or Tacrolimus).remaining patients (others, N ¼ 71, Fig. 3 panel B). Accordingly a
highly signiﬁcant difference in 5 years survival was observed be-
tween patients with a viral etiology of liver disease experiencing
either AS or NAS (16/23) and the remaining patients (104/112,
Mantel Cox p ¼ 0.001). At Cox proportional hazard model, the
interaction between the viral etiology of liver disease with the
occurrence of biliary strictures was found to be an independent
predictor of death within 5 years (O.R. ¼ 3.76, 95% C.I. ¼ 1.34e10.5,
improvement of chi square p ¼ 0.005) in conjunction with CSA use
(O.R. ¼ 3.52, 95% C.I. ¼ 1.18e10.5, improvement of chi square
p ¼ 0.026).4. Discussion
Biliary complications are a major source of morbidity after LT.
Classiﬁcation systems are based mainly on the time of occurrence,
etiology and localization. AS (stenosis or leak) develop later and are
distinguished from NAS that typically occur earlier after LT [2,19].
Risk factors for AS occurrence include older donor age, use of Kehr T
tube, marginal grafts, prolonged ischemia time and split liver
transplantation [1,3].
The frequency of biliary strictures after LT has been reported to
be quite variable. In the present paper the overall incidence of
biliary strictures was about 32%, higher compared towhat observed
in other retrospective series [2,4]. This can be explained by the fact
that in this study donors were older in comparison to what re-
ported in themajor series of liver transplantation performed in USA
[20]. Moreover, about 14% of the recipients underwent biliary
reconstruction with the insertion of a Kehr T tube. The relevance of
this procedure in inﬂuencing AS occurrence in the present study
was conﬁrmed both in the univariate and in the multivariate
analysis.
Although AS could be mainly considered as the ﬁnal result of a
ﬁbrotic process elicited by mechanical or ischemic injuries [1], a
role of the immunological response in modulating inﬂammation
and scarring may be advocated. In fact, it has been shown that AS
are more prevalent in recipients who present early and severe HCV
recurrence compared to those with late and mild recurrence [21],
suggesting that a stronger immune reaction may facilitate inﬂam-
mation and scarring.
In HCV positives donor and recipient IL-28B rs12979860 genetic
polymorphisms inﬂuence both the severity of HCV recurrence and
the probability to achieve sustained viral response after interferon
and ribavirin therapy [13]. In fact, these polymorphisms are in
linkage disequilibrium with SS469415590 T/T or DG of Interferon-
l4 gene [22]. The carriage of IL-28B rs12979860C/C genotype was
associated with the carriage of Interferon-l4 SS469415590 Τ/Τ
genotype. This genotype leads to a frame-shift that inactivates the
gene and in turn determines HCV clearance and a positive treat-
ment outcome [23]. IL-28B genetic polymorphisms have also been
found to be associated with the development of acute cellular
rejection (ACR) after LT [17], a condition strictly related to the
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Fig. 3. Five years survival in recipients who completed at least one year of follow-up after liver transplantation (N ¼ 135) according to the occurrence of biliary strictures either
anastomotic or not anastomotic. Panel A refers to recipients with viral (HCV þ HBV) etiology of liver disease (N ¼ 64). Panel B refers to recipients with no viral etiologies of liver
disease (N ¼ 71).
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rying the rs12979860C/C genotype experienced more severe ACR
episodes compared to those carrying the T/* genotype [17].
Accordingly, AS were found to be more frequent in recipients
carrying the rs12979860C/C compared to those carrying C/T or T/T
genotypes. What appears more intriguing is the observation that
the carriage of rs12979860C/C genotype exerts its maximal inﬂu-
ence in determining AS in conjunction with the CSA use. A simple
explanation for this novel result is unknown; nevertheless it should
be pointed out that CSA alters hepato-biliary function by perturb-
ing biliary ﬂow and bile acid secretion [24]. Finally, the interaction
observed between CSA and rs12979860C/C polymorphism parallels
that found between the carriage of rs12979860C/C polymorphism
and CSA use in conditioning a favorable antiviral response in
recurrent hepatitis C [14].
Studies reporting the association between occurrence of biliary
complications and worse graft and patient survival have been
published [25,26]. Nevertheless, it must be emphasized that these
results might be limited by the inﬂuence of different kinds of
clinical management of biliary complications, i.e. conservative-
endoscopic or invasive-surgical treatment. In this regard the se-
ries reported here were managed in all the cases with a
conservative-endoscopic or percutaneous approach. Indeed, a
worse effect on patient survival, determined by the presence of
biliary complications, was conﬁrmed in the present paper. The ef-
fect was maximally evident in recipients with the viral etiology of
liver disease (HCV and HBV) and disappeared in those with non-
viral etiologies. The data was reinforced by the result of multivar-
iate analysis that highlighted the effect of biliary complications in
conditioning a worse patient survival in HBV and HCV positive
recipients.
In conclusion, despite the advances in both operative and
therapeutic modalities biliary complications remain the Achille's
heel of LT. In recipients carrying rs12979860 IL-28B C/C genotype
the use of CSA seem to contribute to enhance the probability of
developing biliary complications and in HBV and HCV positives to
reduce patients survival. If conﬁrmed in larger studies the use of
CSA in these patients could be revised.Ethical approval
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